Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923466 · ClinicalTrials.gov registry record · Phase 1
Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors
A Phase 1 study, sponsored by Vyriad.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT02923466 is a Phase 1 study that has completed, run by Vyriad. The registered enrollment target is 76 participants.
The verdict
NCT02923466, a Phase 1 study, has completed, sponsored by Vyriad.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a three-part open label phase 1 study designed to determine the safety profile, MTD, PK and tumor and biomarker response after IT or IV administration of a single dose of VSV-IFNβ-NIS, or combined IT followed by IV VSV-IFNβ-NIS, with or without IV avelumab every two weeks, in patients with refractory advanced/metastatic solid tumors.
Interventions
- BIOLOGICAL VSV-IFNβ-NIS
- BIOLOGICAL VSV-IFNβ-NIS and avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2017-04-17 |
| Est. Completion | 2022-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02923466
The ClinicalTrials.gov registry entry for NCT02923466 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyriad, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VSV-IFNβ-NIS is the first listed.
NCT02923466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02923466 about?
NCT02923466 is a clinical study titled "Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors". This is a three-part open label phase 1 study designed to determine the safety profile, MTD, PK and tumor and biomarker response after IT or IV administration of a single dose of VSV-IFNβ-NIS, or combined IT followed by IV VSV-IFNβ-NIS, with or without IV avelumab every two weeks, in patients with r...
What is the current status of trial NCT02923466?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2017-04-17. Estimated completion is 2022-04-22.
What interventions are being tested in trial NCT02923466?
The interventions under investigation include: VSV-IFNβ-NIS (BIOLOGICAL), VSV-IFNβ-NIS and avelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02923466?
This trial is sponsored by Vyriad, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.